All In Biotech

Drug Trial Radar · NCT07460518

Tranexamic Acid for Bleeding Reduction During TURP Surgery

Tranexamic Acid for Perioperative Haemostatic Optimisation During Transurethral Resection of the Prostate: A Randomized Quadruple-Blind Placebo-Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Hamza NajoutAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation. This prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia. Participants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact. The study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.

Conditions

  • Benign Prostatic Hyperplasia
  • Transurethral Resection of the Prostate
  • Perioperative Bleeding
  • Anemia, Postoperative

Interventions

  • Tranexamic AcidDrug

    Intravenous tranexamic acid administered at a dose of 10 mg/kg approximately 30 minutes before surgical resection to reduce perioperative bleeding during transurethral resection of the prostate.

  • Placebo (Normal Saline)Drug

    Intravenous administration of normal saline placebo prepared to be identical in appearance and volume to the tranexamic acid solution to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Hemoglobin Mass Recovered in Irrigation EffluentTime frame: During surgery (from start of resection to end of procedure, up to 3 hours)
  2. Postoperative Hemoglobin ConcentrationTime frame: 24 hours after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mohammed V Military Teaching Hospital

    Rabat, Morocco · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.